首页 > 市场调查报告书 > 製药

骨疾病

骨关节炎药物市场规模、份额和成长分析（按药物类型、解剖部位、给药途径、销售管道、最终用途和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1897199

骨关节炎药物市场规模、份额和成长分析（按药物类型、解剖部位、给药途径、销售管道、最终用途和地区划分）－2026-2033年产业预测

Osteoarthritis Therapeutics Market Size, Share, and Growth Analysis, By Drug Type, By Anatomy, By Route of Administration, By Sales Channel, By End Use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 166 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，骨关节炎治疗市场规模将达到 101.6 亿美元，到 2025 年将达到 108.6 亿美元，到 2033 年将达到 185.1 亿美元，预测期（2026-2033 年）的复合年增长率为 6.9%。

骨关节炎治疗市场正经历显着增长，这主要受该疾病盛行率不断上升的推动，尤其是在老年人中。美国有相当一部分人口患有骨关节炎，凸显了有效治疗方法的迫切性。疾病认知的进步和创新治疗方法的发展进一步推动了这项需求。女性罹病风险较高，这主要是由于肌肉骨骼异常、荷尔蒙变化以及肥胖症盛行率较高等因素造成的，而肥胖症会增加骨关节炎的发生率。骨关节炎的复杂性，例如其增厚且无血管的组织，给治疗带来了挑战。然而，关节内给药系统的进步以及对缓解疾病药物的关注，有望改善治疗效果，并推动该领域持续的研究和开发。

骨关节炎药物市场驱动因素

骨关节炎治疗市场预计将迎来显着增长，主要驱动因素是老龄化社会（尤其是北美和欧洲等已开发地区）中退化性关节退化性疾病的日益增多。随着老龄化增长，罹患骨关节炎的风险也随之增加，因此对有效治疗方法的需求也日益增长。这一人口趋势推动了治疗方案的需求和创新，医疗保健机构和製药公司正努力应对与这种慢性疾病管理相关的挑战。因此，市场预计将会扩张，这反映出老年骨关节炎患者对先进治疗方法的迫切需求。

限制骨关节炎药物市场的因素

传统骨关节炎治疗方法（例如非类固醇消炎剂(NSAIDs) 和皮质类固醇）的潜在副作用是阻碍因素市场发展的重要因素。长期使用这些药物可能导致严重的併发症，例如胃肠道疾病和心血管问题。因此，这些治疗方法的副作用阻碍了患者的接受度，并促使人们寻求更安全的替代疗法。患者偏好的这些转变最终阻碍了传统骨关节炎治疗方法的广泛应用，并凸显了开发更安全、更有效的治疗方案来应对这种常见疾病的必要性。

骨关节炎治疗市场趋势

在骨关节炎药物市场，微创治疗方法（例如黏弹性置换疗法和生物製药注射）的普及是一个显着的趋势。与传统手术相比，这些治疗方法能够有效缓解疼痛、改善关节功能并缩短恢復时间。随着患者和医疗服务提供者日益认识到这些疗法的优势（例如，改善治疗效果和减少恢復时间），微创疗法正逐渐受到重视。这种日益增长的偏好标誌着治疗模式的转变，推动了微创解决方案的创新和投资，最终将重塑骨关节炎的管理和治疗方法格局。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Pfizer Inc.（USA）
Novartis AG（Switzerland）
Sanofi SA（France）
Johnson & Johnson（USA）
Eli Lilly and Company（USA）
Merck & Co., Inc.（USA）
Takeda Pharmaceutical Company Limited（Japan）
AbbVie Inc.（USA）
Amgen Inc.（USA）
Regeneron Pharmaceuticals, Inc.（USA）
Flexion Therapeutics, Inc.（USA）
Seikagaku Corporation（Japan）
TissueGene, Inc.（South Korea）
Anika Therapeutics, Inc.（USA）
Ampio Pharmaceuticals, Inc.（USA）
BioDelivery Sciences International, Inc.（USA）
Bone Therapeutics SA（Belgium）
Kolon TissueGene, Inc.（South Korea）
Centrexion Therapeutics Corporation（USA）
Kiniksa Pharmaceuticals, Ltd.（Bermuda）

结论与建议

简介目录

Product Code: SQMIG30K2057

Osteoarthritis Therapeutics Market size was valued at USD 10.16 Billion in 2024 and is poised to grow from USD 10.86 Billion in 2025 to USD 18.51 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The osteoarthritis therapeutics market is experiencing significant growth driven by the rising prevalence of the condition, particularly among the aging population. A substantial portion of the American population suffers from osteoarthritis, underscoring the urgent need for effective treatment options. This demand is further amplified by advancements in disease understanding and the development of innovative therapies. Women are at heightened risk due to factors such as musculoskeletal abnormalities and hormonal changes, as well as a higher prevalence of obesity, which compounds the incidence of osteoarthritis. The complex nature of osteoarthritis, characterized by thick and avascular tissue, presents management challenges; however, advancements in intra-articular drug delivery systems and a focus on disease-modifying medications hold promise for enhancing treatment efficacy and fostering ongoing research and development in the field.

Top-down and bottom-up approaches were used to estimate and validate the size of the Osteoarthritis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Osteoarthritis Therapeutics Market Segments Analysis

Global Osteoarthritis Therapeutics Market is segmented by Drug Type, Anatomy, Route of Administration, Sales Channel, End Use and region. Based on Drug Type, the market is segmented into Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics, Corticosteroids and Others. Based on Anatomy, the market is segmented into Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis and Others. Based on Route of Administration, the market is segmented into Parenteral Route, Topical Route and Oral Route. Based on Sales Channel, the market is segmented into Prescription Drugs and Over-the-Counter Drugs. Based on End Use, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Osteoarthritis Therapeutics Market

The osteoarthritis therapeutics market is poised for significant growth, primarily fueled by the increasing prevalence of joint degenerative diseases among the aging population, particularly in developed regions like North America and Europe. As individuals age, the likelihood of experiencing osteoarthritis rises, creating a heightened need for effective treatment options. This demographic trend is driving both demand and innovation in therapeutic solutions, as healthcare providers and pharmaceutical companies seek to address the challenges associated with managing this chronic condition. Consequently, the market is expected to expand, reflecting the urgent need for advanced therapeutics tailored to older adults suffering from osteoarthritis.

Restraints in the Osteoarthritis Therapeutics Market

The potential side effects linked to traditional osteoarthritis treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, pose a significant limitation in the market. Long-term usage of these medications can result in serious complications, such as gastrointestinal disorders and cardiovascular problems. Consequently, the adverse effects associated with these therapies deter patients from utilizing them, prompting a search for safer alternatives. This shift in patient preference ultimately hampers the widespread adoption of conventional osteoarthritis treatments, highlighting the need for safer and more effective options in managing this prevalent condition.

Market Trends of the Osteoarthritis Therapeutics Market

The osteoarthritis therapeutics market is witnessing a significant trend towards the adoption of minimally invasive treatments, such as viscosupplementation and biologic injections. These therapies offer effective pain relief and enhance joint functionality, all while requiring less recovery time compared to traditional surgical interventions. As both patients and healthcare providers increasingly recognize the benefits of these options-namely improved outcomes and reduced downtime-minimally invasive alternatives are gaining traction. This growing preference marks a shift in treatment paradigms, encouraging innovation and investment in less invasive solutions, ultimately reshaping the landscape of osteoarthritis management and treatment approaches.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Osteoarthritis Therapeutics Market Size by Drug Type & CAGR (2026-2033)

Market Overview
Viscosupplementation Agents
Nonsteroidal Anti-inflammatory Drugs
- Naproxen
- Aspirin
- Diclofenac
- Ibuprofen
- Celecoxib
- Meloxicam
- Piroxicam
- Ketoprofen
- Other NSAIDs
Analgesics
- Duloxetine
- Acetaminophen
Corticosteroids
Others

Global Osteoarthritis Therapeutics Market Size by Anatomy & CAGR (2026-2033)

Market Overview
Knee Osteoarthritis
Hip Osteoarthritis
Hand Osteoarthritis
Others

Global Osteoarthritis Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Parenteral Route
- Hyaluronic Acid Injections
- Corticosteroid Injections
- Platelet-rich Plasma (PRP) Injections
- Placental Tissue Matrix (PTM) Injections
- Acetylsalicylic Acid (ASA) Injections
- Others
Topical Route
Oral Route

Global Osteoarthritis Therapeutics Market Size by Sales Channel & CAGR (2026-2033)

Market Overview
Prescription Drugs
Over-the-Counter Drugs

Global Osteoarthritis Therapeutics Market Size by End Use & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Others

Global Osteoarthritis Therapeutics Market Size & CAGR (2026-2033)

North America (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
- US
- Canada
Europe (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Flexion Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seikagaku Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TissueGene, Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Anika Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ampio Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioDelivery Sciences International, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bone Therapeutics SA (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kolon TissueGene, Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Centrexion Therapeutics Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kiniksa Pharmaceuticals, Ltd. (Bermuda)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments